证券代码：603392 证券简称：万泰生物 公告编号：2025-029 北京万泰生物药业股份有限公司 关于使用部分闲置募集资金 进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 履行的审议程序：北京万泰生物药业股份有限公司（以下简称"公司"） 于2025年1月14日召开第六届董事会第六次会议、第六届监事会第六次会议，审 议通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司使用最 高额度不超过人民币15亿元（含）的暂时闲置非公开发行股票募集资金适时投资 安全性高、流动性好的保本型产品，单项产品期限最长不超过12个月。该额度自 公司董事会审议通过之日起12个月内有效，可由公司及全资子公司共同循环滚动 使用。具体内容详见公司于指定信息披露媒体披露的《北京万泰生物药业股份有 限公司关于使用部分闲置募集资金进行现金管理的公告》（公告编号：2025-004）。 一、本次现金管理概况 （一）现金管理目的 2、募集资金的基本情况 经中国证券监督管理委员会《关于核准北京万泰生物药业股份有限公司非 ...

北京市中伦律师事务所 关于北京万泰生物药业股份有限公司 2024 年年度股东大会的法律意见书 二〇二五年五月 北京市中伦律师事务所 2 法律意见书 公司关于本次会议的相关公告一起披露，并就本法律意见书承担相应的法律责任。 为出具本法律意见书，本所律师对本次会议的相关文件资料及其他事项进行 了必要的核查。基于核查工作，本所律师依照中国律师业公认的业务标准、道德 规范和勤勉尽责精神，出具法律意见如下： 关于北京万泰生物药业股份有限公司 2024 年年度股东大会的法律意见书 致：北京万泰生物药业股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受北京万泰生物药业股份有限 公司（以下简称"公司"）的委托，就公司 2024 年年度股东大会（以下简称"本次 会议"）相关事宜，根据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司股东大会规则》《上海证券交易所股票上市规则》等法律、法规和规 范性文件及现行有效的《北京万泰生物药业股份有限公司章程》（以下简称"《公 司章程》"），依法出具本法律意见书。 本法律意见书仅就本次会议的召集和召开程序、出席会议人员资格、召集人 资格、本次会议表决程序及表决结果等事项发 ...

证券代码：603392 证券简称：万泰生物 公告编号：2025-028 北京万泰生物药业股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 8 日 (二)股东大会召开的地点：北京市昌平区创新路 7 号公司会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 292 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 985,797,290 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 77.9660 | | 份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集并发布公告通知，由公司董事长邱子欣先生 主持。会议表决方式为现场和网络投票相结合，本次大会的召集与召开程序、出 席会议人 ...

Group 1: WanTai Bio - WanTai Bio announced that its HIV urine self-test kit has received prequalification (PQ) certification from the World Health Organization (WHO), marking it as the first HIV antibody urine self-test kit globally to achieve this status [1] - This certification allows the product to participate in procurement projects by the United Nations and other global multilateral organizations, enhancing the company's international competitiveness [1] - The recognition from WHO is expected to boost investor confidence in the company's research and market potential [1] Group 2: East China Pharmaceutical - East China Pharmaceutical's subsidiary received approval from the National Medical Products Administration (NMPA) for the clinical trial of HDM2005, an antibody-drug conjugate targeting ROR1 for treating diffuse large B-cell lymphoma (DLBCL) [2] - The drug is currently in the fifth dose escalation phase of its clinical trial in China, with no dose-limiting toxicities reported so far [2] - The approval of HDM2005's clinical trial represents a significant advancement in the company's research and development in the oncology field [3] Group 3: GuiChuang TongQiao - GuiChuang TongQiao announced that it will remove the "B" designation from its stock name starting May 9, 2025, indicating that it no longer falls under the category of unprofitable companies [4] - This change reflects the company's achievement of higher operational and performance standards, which is expected to enhance its influence in the capital market and investor recognition [4]

证券代码：603392 证券简称：万泰生物 公告编号：2025-027 北京万泰生物药业股份有限公司 关于艾滋抗体尿液自检试剂通过 WHO 的 PQ 认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 疗，95%接受抗病毒治疗的感染者病毒得到抑制）2030 战略，持续为 2030 全球 "终结艾滋病流行"，保护人类健康，贡献中国力量。 二、获认证产品信息 产品名称：人类免疫缺陷病毒 1 型尿液抗体检测试剂盒（胶体金法）（英文 名称：HIV SELF TEST BY URINE – Human Immunodeficiency Virus (HIV) Type-I Urine Antibody Diagnostic Kit (Colloidal Gold)） 预期用途：用于体外定性检测人尿液样本中的人类免疫缺陷病毒 1 型（HIV-1） 抗体，可用于消费者自测。 规格：1 人份/盒，10 人份/盒，50 人份/盒 三、对公司的影响及风险提示 作为全球首款 HIV 抗体尿液自检试剂盒，获得 WHO PQ 认证意味着公司的 ...

Group 1 - The company reported a significant decline in Q1 2025 performance, with revenue of 401 million yuan, a year-on-year decrease of 46.76%, and a net loss of 53 million yuan, primarily due to challenges in the vaccine segment from market adjustments and government procurement [1] - The nine-valent HPV vaccine is in the application stage for market approval, with progress on clinical trials and commercial production conditions being met, indicating a positive outlook for future revenue generation [2] - The company anticipates a recovery in operating performance as the nine-valent HPV vaccine and other products receive approval, projecting revenues of 3.17 billion yuan, 11.4 billion yuan, and 28.63 billion yuan for 2025 to 2027, with net profits of 350 million yuan, 2.13 billion yuan, and 6.01 billion yuan respectively [3] Group 2 - The nine-valent HPV vaccine is expected to reach a sales peak of 22.8 billion yuan, with a valuation of 86.5 billion yuan based on a 4x PS multiple and a 95% success rate for market approval, highlighting its potential as a key driver for the company's future performance [3] - The company maintains an "Accumulate-A" investment rating, reflecting confidence in the nine-valent HPV vaccine's market potential and the overall recovery of the company's financial performance [3]

Investment Rating - The investment rating for the company is "Accumulate-A" with a target price of 68.33 CNY over the next six months [3][4]. Core Views - The company's performance in Q1 2025 was under pressure, with a revenue of 401 million CNY, a year-on-year decline of 46.76%, and a net loss of 53 million CNY. This decline is attributed to the vaccine segment facing market adjustments, government procurement, and the expansion of the nine-valent HPV vaccine age group, leading to lower-than-expected sales [1]. - The nine-valent HPV vaccine is in the listing application stage, with expectations for its contribution to future revenue. The clinical trials are progressing well, and commercial production conditions are ready. The company anticipates that the launch of this vaccine will help restore its operational performance [2]. Summary by Sections Financial Performance - In 2025, the company is projected to achieve revenues of 3.17 billion CNY, 11.4 billion CNY in 2026, and 28.63 billion CNY in 2027. Net profits are expected to be 350 million CNY, 2.13 billion CNY, and 6.01 billion CNY for the same years respectively [3][10]. - The company’s revenue growth rate is forecasted to be -50.7% in 2023, -59.3% in 2024, followed by a recovery to 41.0% in 2025, 259.9% in 2026, and 151.3% in 2027 [11]. Market Potential - The nine-valent HPV vaccine is expected to reach a peak sales value of 22.8 billion CNY, assuming a cumulative vaccination penetration rate of over 50% among eligible women. The estimated valuation of the company based on this product is 86.5 billion CNY, considering a 4x price-to-sales ratio and a 95% success rate for the product launch [3][10]. Stock Performance - As of April 30, 2025, the stock price was 65.41 CNY, with a 12-month price range of 63.3 to 83.8 CNY. The total market capitalization is approximately 82.75 billion CNY [4][5].

Core Viewpoint - WanTai Biologics (603392.SH) reported a significant decline in performance, with a 91.49% drop in net profit for 2024, attributed to challenges in the vaccine sector, including competition and government procurement impacts [1][2][9]. Financial Performance - For 2024, WanTai Biologics reported total revenue of 2.245 billion yuan, a decrease of 59.25% compared to 2023, and a net profit of 106 million yuan, down 91.49% year-on-year [2][3]. - The company recorded a non-recurring net profit of -186 million yuan, reflecting a change of -117.29% year-on-year [2][3]. - In the first quarter of 2025, the company continued to experience a downward trend, with revenue of 401 million yuan, a decline of 4.76%, and a net loss of 52.78 million yuan, marking a 141.98% decrease year-on-year [2][3]. Vaccine Sector Challenges - The decline in performance is primarily due to the vaccine segment facing market adjustments, government procurement pressures, and competition from domestic rivals [9][20]. - The price of the company's bivalent HPV vaccine has been under pressure, with the bidding price range dropping from 329-344 yuan per bottle in 2020-2022 to 63-344 yuan in 2024 [20][21]. - The company’s vaccine sales have significantly decreased, with inventory levels showing a substantial drop in production and sales compared to previous years [24][25]. Clinical Development and Market Position - WanTai Biologics is advancing its nine-valent HPV vaccine, which is currently in Phase III clinical trials, with plans for commercialization pending regulatory approval [16][19]. - The company has developed the first domestic bivalent HPV vaccine, which has gained market access in China and 21 other countries [9][12]. - The competitive landscape is intensifying, with other companies like Watson Bio also entering the HPV vaccine market, further impacting WanTai's market share [20][19]. Future Outlook - The company is focusing on its in vitro diagnostic business, which has shown more stability compared to the vaccine sector, and has appointed a new general manager with extensive experience in diagnostics [25].

北京万泰生物药业股份有限公司 2024 年年度股东大会会议资料 北 京 万 泰 生 物 药 业 股 份 有 限 公 司 2024 年年度股东大会会议资料 股票简称：万泰生物 股票代码：603392 2025 年 5 月 1 北京万泰生物药业股份有限公司 2024 年年度股东大会会议资料 北京万泰生物药业股份有限公司 会议资料目录 三、会议议案 议案 8：《关于续聘容诚会计师事务所（特殊普通合伙）为公司 2025 年度 审计机构和内部控制审计机构的议案》 议案 9：《关于 2025 年度向金融机构申请综合授信额度暨预计担保额度的 议案》 听取《独立董事 2024 年度述职报告》 2 一、股东大会须知 二、会议议程 议案 1：《2024 年度董事会工作报告》 议案 2：《2024 年度监事会工作报告》 议案 3：《2024 年年度报告全文及其摘要》 议案 4：《2024 年度财务决算报告》 议案 5：《2024 年度利润分配预案》 议案 6：《2025 年度董事薪酬方案》 6.01 独立董事薪酬 6.02 非独立董事薪酬 议案 7：《2025 年度监事薪酬方案》 议案 10：《关于修订<公司章程>的议案》 议案 ...

Policy Developments - Seven departments, including the Ministry of Industry and Information Technology, issued the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)", emphasizing the integration of artificial intelligence across the pharmaceutical supply chain [1] Drug and Device Approvals - Kangtai Biological announced that its subsidiary Minhai Biological's application for the marketing authorization of an adsorbed tetanus vaccine has been accepted by the National Medical Products Administration [2] - Hendi Pharmaceutical received approval for the marketing application of arginine ibuprofen, a non-steroidal anti-inflammatory drug with superior solubility and faster absorption compared to regular ibuprofen [3] - Tianyao Pharmaceutical's subsidiary obtained a drug registration certificate for injectable hydrocortisone sodium succinate, used for critical conditions such as allergic shock and severe adrenal insufficiency [4] Financial Reports - Wantai Biological reported a net loss of 52.78 million yuan in Q1 2025, with revenue of 401 million yuan, a year-on-year decline of 46.76%, primarily due to market adjustments and government procurement impacts [5] - Heng Rui Pharmaceutical's Q1 2025 report showed a revenue of 7.206 billion yuan, a year-on-year increase of 20.14%, and a net profit of 1.874 billion yuan, up 36.9%, largely due to a licensing payment from IDEAYA [6] - Kingstone Pharma reported a revenue of 291 million yuan in Q1 2025, down 19.65%, with a net profit of 62.85 million yuan, a decrease of 30.02% [8] - Baijun Medical achieved a revenue of 100 million yuan in Q1 2025, a 31.3% increase, with a net profit of 32.50 million yuan, up 290.69%, driven by stable sales of existing products and successful new product launches [9] Capital Market Activities - Tonghe Pharmaceutical plans to invest 11 million yuan to increase its stake in Hangzhou Boya Biomedical Co., Ltd., raising its ownership from 16.34% to 24.93% [10] - Chengyuan Biotechnology announced the completion of several million yuan in equity financing, aimed at upgrading its gene synthesis technology platform [11] Industry Developments - Zhang Wenhong's team announced significant progress in developing a broad-spectrum antiviral drug for monkeypox, which is set to enter clinical approval stages [12] - Qianxin Biotechnology signed a licensing agreement with Caldera Therapeutics for its long-acting dual antibody QX030N, granting global exclusive rights for development and commercialization [13] Public Sentiment Alerts - Weiming Pharmaceutical announced that its important subsidiary, Tianjin Weiming, was suspended from production and sales, which could trigger further risk warnings if production does not resume within three months [14]